Top Markets
Coin of the day
Bellicum Pharmaceuticals, Inc. Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc.

BLCM
株式のランク #38880
Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage... Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.
株価
$0.07475
最終同期: 2024-03-04
時価総額
$755.60K
変化(1日)
-6.68%
変化(1年)
0.00%
US
取引 Bellicum Pharmaceuticals, Inc. (BLCM)

カテゴリー

Bellicum Pharmaceuticals, Inc.(BLCM)の配当利回りの履歴
Bellicum Pharmaceuticals, Inc.(銘柄コード: BLCM)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Bellicum Pharmaceuticals, Inc.(BLCM)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)